Story perspectives

New Therapies Show Promise Against Triple Negative Breast Cancer

10/4/2025

40 8

Summary

Story summary

EZH2 inhibition may treat triple negative breast cancer (TNBC), restoring normal cell division and reducing metastasis in preclinical models.
Findings from Weill Cornell Medicine challenge chromosomal-instability strategies.
Johns Hopkins University researchers show induction of tertiary lymphoid structures (TLS) in immune-cold tumors via STING and LT?R, boosting immune recruitment.
Future trials may test EZH2 inhibitors and TLS-inducing therapies for aggressive cancers.

1 of 1

Story summary

EZH2 inhibition may treat triple negative breast cancer (TNBC), restoring normal cell division and reducing metastasis in preclinical models.
Findings from Weill Cornell Medicine challenge chromosomal-instability strategies.
Johns Hopkins University researchers show induction of tertiary lymphoid structures (TLS) in immune-cold tumors via STING and LT?R, boosting immune recruitment.
Future trials may test EZH2 inhibitors and TLS-inducing therapies for aggressive cancers.